Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI eye scanner could catch glaucoma before it steals your sight

NCT ID NCT07550712

Diagnosis Sponsor: Acer Medical Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an AI tool called VeriSee GLC that analyzes color images of the back of the eye to find signs of glaucoma. Researchers looked at 773 adults' existing eye images to see how well the AI could identify people who might have glaucoma, comparing its results to a panel of eye experts. The goal is to give doctors a reliable screening tool to catch glaucoma earlier and refer patients for a full exam.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VeriSee GLC (AI software for analyzing eye images)
What this could lead to
If successful, this AI tool could help eye doctors quickly identify people who might have glaucoma, leading to earlier referral and treatment.
What could go wrong
This was a retrospective study using existing images, not a real-world test. The AI is meant to assist, not replace a doctor, and may not work as well in all populations or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

773 people

The number who actually took part.

Started

Aug 2024

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of de-identified retrospective cases collected from National Taiwan University Hospital between February 1, 2022 and December 31, 2023. Cases were identified based on predefined ICD-10 code criteria, with exclusions applied for cataracts, acute angle-closure glaucoma, and prior ocular laser procedures. All cases were further screened according to predefined image inclusion and exclusion criteria, including image resolution, field of view, refractive status, and the visibility of the optic disc and retinal nerve fiber layer (RNFL), as determined by healthcare professionals. A total of 773 evaluable cases were included, of which 749 images were successfully analyzed by VeriSee GLC.

Ages

20 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The adult color fundus image (aged 20 and above) 2. The requirements of color fundus image * The resolution of image is 1024 × 1024 pixels or higher; * The angle view of image is 45-or 50-degree. * Images captured from eyes with myopia not exceeding -10 diopters. 3. The color fundus image includes the optic disc and RNFL areas, and one of these areas is evaluable, as judged by the healthcare professionals. Exclusion Criteria: 1. The color fundus images previously used by VeriSee GLC during the development process and pre-clinical test. 2. A color fundus image of patients with cataracts, acute angle closure glaucoma or those who have undergone retinal laser surgery. 3. The optic disc and RNFL areas in the color fundus images is invisible to determine the disease condition as judged by the healthcare professionals.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

glaucoma ocular hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Glaucoma

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.